Dr. Stephanie Venn-Watson is a veterinary epidemiologist, public health scientist, and serial entrepreneur known for her groundbreaking discovery of C15:0 (pentadecanoic acid), the first essential fatty acid identified in over 90 years. Her research with aging Navy dolphins led to the development of Fatty15, a pure C15:0 supplement aimed at promoting cellular health and longevity. As co-founder and CEO of Seraphina Therapeutics, Dr. Venn-Watson holds over 60 patents and has authored more than 80 peer-reviewed publications. Her work has been featured on NPR, CBS, BBC, and National Geographic. She has received accolades such as the Department of Health and Human Services Secretary’s Award for Innovations in Disease Prevention and Health Promotion, and Boehringer Ingelheim’s Innovation Award. Dr. Venn-Watson earned her B.S. in Animal Physiology and Neuroscience from UC San Diego, her D.V.M. from Tufts University, and her M.P.H. from Emory University.